Integrating clinical and molecular approaches to improve survival in esophageal squamous cell carcinoma

Abstract

Esophageal squamous cell carcinoma continues to pose a significant global health burden due to its aggressive nature and poor prognosis, often diagnosed at an advanced stage. This retrospective study by Ren et al aims to identify long-term survival outcomes and the associated risk factors for esophageal squamous cell carcinoma patients, employing Kaplan-Meier survival analysis and Cox regression models. The study highlights critical prognostic factors such as tumor stage, age, gender, and treatment modality. The authors emphasize the importance of clinical factors in predicting survival and underscore the necessity of incorporating molecular biomarkers and psychosocial elements into survival models for more accurate predictions. While the study offers valuable insights, it also points to the potential for integrating modern therapies such as chemoradiotherapy and targeted treatments to improve survival outcomes. Future research should focus on prospective cohort studies, external validation, and the development of personalized treatment strategies that combine clinical, molecular, and psychosocial factors to optimize patient care.

Key Words: Esophageal squamous cell carcinoma; Survival outcomes; Prognostic factors; Kaplan-Meier; Prognosis; Personalized medicine

Core Tip: This study underscores the key prognostic factors affecting long-term survival in esophageal squamous cell carcinoma, with a particular focus on tumor stage, age, gender, and treatment modality. The findings highlight the importance of integrating molecular biomarkers and psychosocial factors into survival models to improve prediction accuracy. Future research should focus on prospective studies and developing personalized treatment strategies that incorporate both traditional and modern therapeutic approaches to improve patient outcomes.

TO THE EDITOR

The article by Ren et al[1] presents a retrospective study investigating long-term survival and risk factors in patients with esophageal squamous cell carcinoma (ESCC). The authors use Kaplan-Meier survival analysis and Cox regression modeling to identify key prognostic factors affecting survival outcomes in ESCC patients. This study addresses a critical issue in oncology, particularly esophageal cancer, by focusing on the squamous cell carcinoma subtype, which remains one of the deadliest forms of esophageal cancer globally[2]. The authors identify several significant risk factors influencing patient survival, including tumor stage, age, gender, and treatment modality. The use of Kaplan-Meier and Cox regression enhances the reliability and robustness of the findings, offering valuable insights into the survival patterns of ESCC patients.

Ren et al’s findings[1] are consistent with a substantial body of literature that identifies tumor stage and age as key prognostic factors in ESCC survival[3-5]. Specifically, studies by Jin et al[6] and Rai et al[7] have similarly found that older age and advanced tumor stages correlate with worse survival outcomes. However, while Ren et al[1] primarily focus on clinical factors such as tumor stage and patient demographics, recent studies, such as those by Zheng et al[8], have expanded the survival model by incorporating molecular biomarkers, improving predictive accuracy. For example, Rai et al[7] demonstrated that combining clinical staging with molecular profiling, including p53 mutations and epidermal growth factor receptor (EGFR) expression, led to more accurate prognosis predictions. This highlights a key opportunity for future research - Ren et al[1] could strengthen their model by integrating molecular and genetic markers, providing a more comprehensive understanding of survival factors in ESCC.

Additionally, Ren et al[1] focus on clinical treatment modalities, particularly radical surgery as the primary therapeutic approach. Their findings underscore the importance of tumor location and perineural invasion in determining patient prognosis[9-11]. In contrast, Jeon et al[12] highlighted superior survival outcomes in locally advanced ESCC patients treated with concurrent chemoradiotherapy compared to single-modality approaches[12]. This emphasizes the necessity of multimodal treatment considerations. Moreover, incorporating genetic, molecular, and psychosocial dimensions into survival models could further refine predictive accuracy. Research by Ko et al[13] indicates that psychosocial factors, including depression and social support, significantly impact survival in cancer patients, including those with ESCC[13]. Additionally, genomic analyses, such as those by Zhang et al[14], identified genetic signatures influencing immune responses and treatment responses. Integrating these genetic factors into survival models would provide a more holistic view of the factors influencing survival in ESCC.

Furthermore, Chen et al[15] have demonstrated that personalized treatment strategies tailored to the genetic and molecular profiles of individual tumors can significantly improve survival outcomes. Chen et al[15] emphasized the importance of identifying patients who are likely to benefit from targeted therapies, such as EGFR or vascular endothelial growth factor inhibitors. Ren et al[1] could consider exploring this approach in their future work, potentially developing a personalized, patient-specific treatment plan that integrates clinical, molecular, and psychosocial data to improve patient outcomes. To further improve the accuracy of survival predictions, Ren et al’s study[1] could be extended to incorporate molecular and genetic profiling. As demonstrated by Zhang et al[14], integrating clinical data with genetic markers, such as EGFR expression or tumor protein p53 mutations, can provide a more personalized and precise approach to treatment. The incorporation of liquid biopsy techniques and next-generation sequencing into survival models would also open new possibilities for early detection and the monitoring of treatment efficacy in ESCC patients.